Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
about
PP2A: The Achilles Heal in MDS with 5q DeletionAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Therapeutic advancement of chronic lymphocytic leukemia.TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.Recent Advances in the 5q- Syndrome.Determination of cellular uptake and intracellular levels of Cenersen (Aezea(®), EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells.
P2860
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase II study of cenersen, an ...... chronic lymphocytic leukemia.
@ast
Phase II study of cenersen, an ...... chronic lymphocytic leukemia.
@en
type
label
Phase II study of cenersen, an ...... chronic lymphocytic leukemia.
@ast
Phase II study of cenersen, an ...... chronic lymphocytic leukemia.
@en
prefLabel
Phase II study of cenersen, an ...... chronic lymphocytic leukemia.
@ast
Phase II study of cenersen, an ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P1433
P1476
Phase II study of cenersen, an ...... chronic lymphocytic leukemia.
@en
P2093
Carlos M DeCastro
Catherine Rehder
Daphne R Friedman
David Rizzieri
F Joseph Daugherty
Harry Cook
J Brice Weinberg
Jon P Gockerman
Joseph O Moore
Karen M B Matta
P2860
P304
P356
10.3109/10428194.2011.610012
P577
2011-09-23T00:00:00Z